Compare Tata Investment with Indoco Remedies - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TATA INVESTMENT vs INDOCO REMEDIES - Comparison Results

TATA INVESTMENT     Change

Tata Investment Corporation is more than 70 years old. It is a non banking financial company (NBFC). The stated objective of the company is to invest in Tata and non-Tata companies, both in the listed and unlisted categories. However, investments in ... More

INDOCO REMEDIES 
   Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TATA INVESTMENT INDOCO REMEDIES TATA INVESTMENT/
INDOCO REMEDIES
 
P/E (TTM) x 38.1 72.2 52.8% View Chart
P/BV x 2.1 4.2 49.6% View Chart
Dividend Yield % 2.0 0.3 615.0%  

Financials

 TATA INVESTMENT   INDOCO REMEDIES
EQUITY SHARE DATA
    TATA INVESTMENT
Mar-18
INDOCO REMEDIES
Mar-18
TATA INVESTMENT/
INDOCO REMEDIES
5-Yr Chart
Click to enlarge
High Rs955317 300.9%   
Low Rs632178 355.0%   
Sales per share (Unadj.) Rs56.4113.1 49.9%  
Earnings per share (Unadj.) Rs44.64.5 998.5%  
Cash flow per share (Unadj.) Rs44.611.8 377.7%  
Dividends per share (Unadj.) Rs20.001.00 2,000.0%  
Dividend yield (eoy) %2.50.4 624.3%  
Book value per share (Unadj.) Rs480.573.2 656.0%  
Shares outstanding (eoy) m55.1092.15 59.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x14.12.2 642.5%   
Avg P/E ratio x17.855.5 32.1%  
P/CF ratio (eoy) x17.821.0 84.8%  
Price / Book Value ratio x1.73.4 48.8%  
Dividend payout %44.822.4 200.3%   
Avg Mkt Cap Rs m43,73022,830 191.5%   
No. of employees `000NA5.5 0.4%   
Total wages/salary Rs m1102,209 5.0%   
Avg. sales/employee Rs Th135,064.81,910.1 7,071.2%   
Avg. wages/employee Rs Th4,765.2405.0 1,176.7%   
Avg. net profit/employee Rs Th106,847.875.5 141,607.1%   
INCOME DATA
Net Sales Rs m3,10610,419 29.8%  
Other income Rs m147 2.1%   
Total revenues Rs m3,10710,466 29.7%   
Gross profit Rs m2,8361,349 210.2%  
Depreciation Rs m1677 0.2%   
Interest Rs m0235 0.0%   
Profit before tax Rs m2,836484 585.9%   
Minority Interest Rs m-10-   
Prior Period Items Rs m900-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m46772 645.0%   
Profit after tax Rs m2,458412 597.1%  
Gross profit margin %91.312.9 705.0%  
Effective tax rate %16.515.0 110.1%   
Net profit margin %79.14.0 2,002.6%  
BALANCE SHEET DATA
Current assets Rs m5265,373 9.8%   
Current liabilities Rs m854,157 2.0%   
Net working cap to sales %14.211.7 121.7%  
Current ratio x6.21.3 480.9%  
Inventory Days Days068 0.0%  
Debtors Days Days1773 22.7%  
Net fixed assets Rs m1366,244 2.2%   
Share capital Rs m551184 299.0%   
"Free" reserves Rs m25,9256,566 394.9%   
Net worth Rs m26,4766,750 392.2%   
Long term debt Rs m01,233 0.0%   
Total assets Rs m26,61912,363 215.3%  
Interest coverage x28,359.03.1 927,159.1%   
Debt to equity ratio x00.2 0.0%  
Sales to assets ratio x0.10.8 13.8%   
Return on assets %9.25.2 176.5%  
Return on equity %9.36.1 152.2%  
Return on capital %11.09.0 122.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m03,762 0.0%   
Fx outflow Rs m01,143 0.0%   
Net fx Rs m02,619 -0.0%   
CASH FLOW
From Operations Rs m6691,227 54.5%  
From Investments Rs m407-1,360 -29.9%  
From Financial Activity Rs m-1,194-388 308.0%  
Net Cashflow Rs m-118-521 22.7%  

Share Holding

Indian Promoters % 73.0 59.2 123.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.5 12.5 36.0%  
FIIs % 1.5 6.0 25.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.0 22.4 93.8%  
Shareholders   25,758 12,805 201.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TATA INVESTMENT With:   REDINGTON  CENTURY PLYBOARDS  COMPACT DISC  TALWALKARS BETTER VALUE  INDIABULLS FIN. SER.  



Today's Market

Sensex, Nifty Recover From Day's Low to End Strong; TCS & Wipro Rally Over 3.5%(Closing)

Indian share markets recouped early losses during closing hours and ended today's volatile session higher, helped by gains in metals and banking stocks.

Related Views on News

Indian Railway Finance Corporation IPO: Should You Apply? (IPO)

Jan 18, 2021

Monopolistic railway financer with impeccable asset quality.

CAMS IPO: Should You Apply? (IPO)

Sep 18, 2020

Does the company having 70% market share of the mutual fund registrar business have sound prospects?

INDOCO REMEDIES Announces Quarterly Results (3QFY20); Net Profit Up 74.9% (Quarterly Result Update)

Jan 27, 2020 | Updated on Jan 27, 2020

For the quarter ended December 2019, INDOCO REMEDIES has posted a net profit of Rs 93 m (up 74.9% YoY). Sales on the other hand came in at Rs 3 bn (up 10.2% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (2QFY20); Net Profit Up 194.1% (Quarterly Result Update)

Nov 5, 2019 | Updated on Nov 5, 2019

For the quarter ended September 2019, INDOCO REMEDIES has posted a net profit of Rs 73 m (up 194.1% YoY). Sales on the other hand came in at Rs 3 bn (up 23.9% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (1QFY20); Net Profit Up 118.1% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, INDOCO REMEDIES has posted a net profit of Rs 22 m (up 118.1% YoY). Sales on the other hand came in at Rs 3 bn (up 16.2% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On...(Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

Why the Market Fell Yesterday(Fast Profits Daily)

Apr 6, 2021

In this video, I'll tell you the two reasons why the market fell on Monday and how you can prepare yourself for such events in the future.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

TATA INVESTMENT SHARE PRICE


Apr 15, 2021 (Close)

TRACK TATA INVESTMENT

  • Track your investment in TATA INVESTMENT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TATA INVESTMENT

TATA INVESTMENT 8-QTR ANALYSIS

COMPARE TATA INVESTMENT WITH

MARKET STATS